NDLI: Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis

Content Provider	Springer Nature : BioMed Central
Author	Gonano, Christopher Sitzwohl, Christian Meitner, Eva Weinstabl, Christian Kettner, Stephan C
Abstract	Introduction Sepsis activates the coagulation system and frequently causes hypercoagulability, which is not detected by routine coagulation tests. A reliable method to evaluate hypercoagulability is thromboelastography (TEG), but this has not so far been used to investigate sepsis-induced hypercoagulability. Antithrombin (AT) in plasma of septic patients is decreased, and administration of AT may therefore reduce the acquired hypercoagulability. Not clear, however, is to what extent supraphysiologic plasma levels of AT decrease the acute hypercoagulability in septic patients. The present study investigates the coagulation profile of septic patients before and during four day high-dose AT therapy. Methods Patients with severe sepsis were randomly assigned to receive either 6,000 IU AT as a bolus infusion followed by a maintenance dose of 250 IU/hour over four days (n = 17) or placebo (n = 16). TEG, platelet count, plasma fibrinogen levels, prothrombin time and activated partial thromboplastin time were assessed at baseline and daily during AT therapy. Results TEG showed a hypercoagulability in both groups at baseline, which was neither reversed by bolus or by maintenance doses of AT. The hypercoagulability was mainly caused by increased plasma fibrinogen, and to a lesser extent by platelets. Plasmatic coagulation as assessed by the prothrombin time and activated partial thromboplastin time was similar in both groups, and did not change during the study period. Conclusion The current study shows a distinct hypercoagulability in patients suffering from severe sepsis, which was not reversed by high-dose AT treatment over four days. This finding supports recent data showing that modulation of coagulatory activation in septic patients by AT does not occur before one week of therapy. Trial registration: Current Control Trials ISRCTN22931023
Related Links	https://ccforum.biomedcentral.com/counter/pdf/10.1186/cc5098.pdf
Ending Page	6
Page Count	6
Starting Page	1
File Format	HTM / HTML
ISSN	13648535
DOI	10.1186/cc5098
Journal	Critical Care
Issue Number	6
Volume Number	10
Language	English
Publisher	BioMed Central
Publisher Date	2006-11-15
Access Restriction	Open
Subject Keyword	Intensive Critical Care Medicine Emergency Medicine Severe Sepsis Septic Patient Abciximab Continuous Renal Replacement Therapy Plasma Fibrinogen
Content Type	Text
Resource Type	Article
Subject	Critical Care and Intensive Care Medicine
Journal Impact Factor	8.8/2023
5-Year Journal Impact Factor	10.4/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

Antithrombin and hypercoagulability in sepsis: insights from thrombelastography?

Is hydroxyethyl starch 130/0.4 safe?

Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock

Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis

Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider

Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!

Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis

Similar Documents

Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

Antithrombin and hypercoagulability in sepsis: insights from thrombelastography?

Is hydroxyethyl starch 130/0.4 safe?

Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock

Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis

Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider

Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!

Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis